Although con- sidered promising for use in drug-eluting stents (DES), tacrolimus failed clinically. Tacrolimus inhibits growth factor production but can also act as a growth factor on vascular smooth muscle cells (VSMC). This unexpected proliferative stimulus could reverse the beneficial effects of the drug on restenosis. We hypothesized that tacrolimus’ association with statins, which lower cholesterol and impair cell proliferation, could restore tacrolimus’ beneficial effect by abrogating the aberrant proliferative stimulus. Additionally, since maintenance of endothelial function represents a challenge for new-generation DES, we investigated the combined effect of tacrolimus and atorvastatin on endothelial cells. Human VSMC and umbilical vein endothelial cells (HUVEC) were incubated with 100 nM tacrolimus and increasing doses of atorvastatin (0–3.0 uM). Atorvastatin plus tacrolimus dose- dependently inhibited VSMC proliferation. The percentage of cells incorporating 5-bromo-2=-deoxyuridine (BrdU) in their DNA was 49 + 14% under basal conditions, 62 + 15% (P = 0.01) with tacrolimus, 40 + 22% with 3 uM atorvastatin, and 30 + 7% (P = 0.05) with 3 uM atorvastatin plus tacrolimus. Atorvastatin downregu- lated beta-catenin, Erk1 and Erk2, and cyclin B in tacrolimus-stimulated VSMC. In contrast, atorvastatin plus tacrolimus did not affect prolif- eration of endothelial cells. The percentage of HUVEC incorporating BrdU in their DNA was 47 + 8% under basal conditions, 58 + 6% (P = 0.01) with tacrolimus, 45 + 4% with 3 uM atorvastatin, and 49 + 1% with 3 uM atorvastatin plus tacrolimus. Both agents stimulated endoglin production by HUVEC. Taken together, these results suggest that, when combined with tacrolimus, atorvastatin exerts a dose-dependent antiproliferative effect on VSMC. In contrast, atorvastatin acts in concert with tacrolimus in HUVEC to stimulate production of endoglin, a factor that has an important role in endo- thelial repair. Our study supports the conclusion that prevention of postcoronary in-stent restenosis and late thrombosis may benefit of concomitant association of tacrolimus and high doses of atorvastatin.

Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells / Giordano, A; Romano, Simona; Monaco, M; Sorrentino, A; Corcione, N; Di Pace, Al; Ferraro, P; Nappo, G; Polimeno, M; Romano, MARIA FIAMMETTA. - In: AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY. - ISSN 0363-6135. - 302:1(2012), pp. 135-142. [10.1152/ajpheart.00490.2011.]

Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells.

ROMANO, SIMONA;ROMANO, MARIA FIAMMETTA
2012

Abstract

Although con- sidered promising for use in drug-eluting stents (DES), tacrolimus failed clinically. Tacrolimus inhibits growth factor production but can also act as a growth factor on vascular smooth muscle cells (VSMC). This unexpected proliferative stimulus could reverse the beneficial effects of the drug on restenosis. We hypothesized that tacrolimus’ association with statins, which lower cholesterol and impair cell proliferation, could restore tacrolimus’ beneficial effect by abrogating the aberrant proliferative stimulus. Additionally, since maintenance of endothelial function represents a challenge for new-generation DES, we investigated the combined effect of tacrolimus and atorvastatin on endothelial cells. Human VSMC and umbilical vein endothelial cells (HUVEC) were incubated with 100 nM tacrolimus and increasing doses of atorvastatin (0–3.0 uM). Atorvastatin plus tacrolimus dose- dependently inhibited VSMC proliferation. The percentage of cells incorporating 5-bromo-2=-deoxyuridine (BrdU) in their DNA was 49 + 14% under basal conditions, 62 + 15% (P = 0.01) with tacrolimus, 40 + 22% with 3 uM atorvastatin, and 30 + 7% (P = 0.05) with 3 uM atorvastatin plus tacrolimus. Atorvastatin downregu- lated beta-catenin, Erk1 and Erk2, and cyclin B in tacrolimus-stimulated VSMC. In contrast, atorvastatin plus tacrolimus did not affect prolif- eration of endothelial cells. The percentage of HUVEC incorporating BrdU in their DNA was 47 + 8% under basal conditions, 58 + 6% (P = 0.01) with tacrolimus, 45 + 4% with 3 uM atorvastatin, and 49 + 1% with 3 uM atorvastatin plus tacrolimus. Both agents stimulated endoglin production by HUVEC. Taken together, these results suggest that, when combined with tacrolimus, atorvastatin exerts a dose-dependent antiproliferative effect on VSMC. In contrast, atorvastatin acts in concert with tacrolimus in HUVEC to stimulate production of endoglin, a factor that has an important role in endo- thelial repair. Our study supports the conclusion that prevention of postcoronary in-stent restenosis and late thrombosis may benefit of concomitant association of tacrolimus and high doses of atorvastatin.
2012
Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells / Giordano, A; Romano, Simona; Monaco, M; Sorrentino, A; Corcione, N; Di Pace, Al; Ferraro, P; Nappo, G; Polimeno, M; Romano, MARIA FIAMMETTA. - In: AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY. - ISSN 0363-6135. - 302:1(2012), pp. 135-142. [10.1152/ajpheart.00490.2011.]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/412038
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact